Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
NCT04409327 · Restorbio Inc. · PHASE2 · terminated · last registry update 2021-02-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient accrual rate” | – | Registry record, Restorbio Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-01-19Results posted on the registry: University of Colorado, Denver, Alisertib + MLN0128 (NCT02719691)
- 2021-10-07Results posted on the registry: Pfizer, PF-05212384 (gedatolisib) + Docetaxel (NCT01920061)
- 2021-07-27Results posted on the registry: The Methodist Hospital Research Institute, TAK-228 + Tamoxifen (NCT02988986)
- 2021-06-23Results posted on the registry: Restorbio Inc., Dactolisib (NCT04668352)
- 2021-02-25Results posted on the registry: Medinol Ltd., a drug against MTOR (NCT01995487)
- 2021-02-24Results posted on the registry: Fox Chase Cancer Center, TAK-228 (NCT02987959)
- 2021-02-21Results posted on the registry: Millennium Pharmaceuticals, Inc., Everolimus + MLN0128 (NCT02724020)
- 2021-02-21Results posted on the registry: Fox Chase Cancer Center, ridaforolimus + vorinostat (NCT01169532)
- 2021-02-16Also stopped (terminated): Angela Taber MD, Ridaforolimus (NCT01212627)
- 2021-01-06Results posted on the registry: Acerta Pharma BV, acalabrutinib + vistusertib (NCT03205046)
- 2021-01-06Also stopped (terminated): Acerta Pharma BV, acalabrutinib + vistusertib (NCT03205046)
- 2020-12-29Results posted on the registry: Dana-Farber Cancer Institute, MLN0128 (NCT02514824)
- 2020-12-22Results posted on the registry: Massachusetts General Hospital, AZD2014 (NCT02831257)
- 2020-12-19Results posted on the registry: Calithera Biosciences, Inc, Fulvestrant + Sapanisertib (NCT02756364)
- 2020-12-16Phase 3 first posted: Restorbio Inc., Dactolisib (NCT04668352)
- 2020-12-08Also stopped (terminated): Novartis Pharmaceuticals, BEZ235 + Paclitaxel (NCT01495247)
- 2020-11-20Also stopped (withdrawn): SWOG Cancer Research Network, Dexamethasone + Docetaxel (NCT04267913)
- 2020-10-28Results posted on the registry: Medinol Ltd., EluNIR Ridaforolimus Eluting Coronary Stent System (NCT03702608)
- 2020-09-24Results posted on the registry: Medinol Ltd., a drug against MTOR (NCT02828917)
- 2020-09-24Results posted on the registry: Medinol Ltd., a drug against MTOR (NCT02834806)
- 2020-09-09Results posted on the registry: Calithera Biosciences, Inc, TAK-228 (NCT03370302)
- 2020-06-09Results posted on the registry: Millennium Pharmaceuticals, Inc., Paclitaxel + Sapanisertib (NCT02725268)
- 2020-05-28Also stopped (terminated): NewLink Genetics Corporation, 1-methyl-D-tryptophan (NCT00739609)
- 2020-04-28Also stopped (withdrawn): Abramson Cancer Center at Penn Medicine, Hydroxychloroquine (HCQ) + Gedatolisib (NCT03400254)
- 2020-04-03Results posted on the registry: Masonic Cancer Center, University of Minnesota, Indoximod + Sipuleucel-T (NCT01560923)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision